Predictive Parameters of a Worse Prognosis in Patients with G2 Neuroendocrine Tumors Treated with Peptide Radio Receptorial Therapy

被引：0
|
作者：
Jandric, J. [1 ]
Laffi, A. [1 ]
Muraglia, L. [1 ]
Zanca, R. [1 ,2 ]
Rodari, M. [1 ]
Evangelista, L. [1 ,2 ]
机构：
[1] IRCCS Humanitas Res Hosp, Rozzano, Italy
[2] Humanitas Univ, Pieve Emanuele Milano, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0598
引用
收藏
页码：S669 / S670
页数：2
相关论文
共 50 条
  • [1] Subgroup analysis of patients with G2 gastroenteropancreatic neuroendocrine tumors
    Hauck, Lisa
    Bitzer, Michael
    Malek, Nisar
    Plentz, Ruben R.
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (01) : 55 - 59
  • [2] Quality Of Life in Patients with Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy
    Wang, Q.
    Librizzi, D.
    Bagheri, S.
    Ebrahimifard, A.
    Luster, M.
    Yousefi, B. H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S246 - S247
  • [3] Subgroup Analysis of Patients with gastro-pancreatic neuroendocrine Tumors G2
    Hauck, L.
    Bitzer, M.
    Malek, N.
    Plentz, R.
    INTERNIST, 2015, 56 : 23 - 23
  • [4] Quality Of Life in Patients with Neuroendocrine Gastroenteropancreatic Tumors Treated with Peptide Receptor Radionuclide Therapy
    Georgakopoulos, A.
    Liotsou, T.
    Chatziioannou, S. N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S691 - S691
  • [5] Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy
    Cordero-Hernandez, Igryl S.
    Ross, Alicia C.
    Dasari, Arvind
    Halperin, Daniel M.
    Chasen, Beth
    Yao, James C.
    ENDOCRINE-RELATED CANCER, 2024, 31 (04)
  • [6] Complete Remission Upon Peptide Receptor Radionuclide Therapy in a G2 Pancreatic Neuroendocrine Tumor
    Weich, Alexander
    Serfling, Sebastian E.
    Yi, Heqing
    Buck, Andreas K.
    Higuchi, Takahiro
    Werner, Rudolf A.
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (04) : 335 - 336
  • [7] Peptide Radio Receptor Therapy induces immune activation in patients with neuroendocrine tumors and might sensitize to immunotherapy
    Buettner, S.
    Detjen, K.
    Galler, M.
    Siefert, J.
    Wiedenmann, B.
    Amthauer, H.
    Tacke, F.
    Roderburg, C.
    Hammerich, L.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 48 - 48
  • [8] Peptide Radio Receptor Therapy sensitizes to immunotherapy by increasing expression of checkpoint molecules in in patients with neuroendocrine tumors
    Buettne, S.
    Wiedenmann, B.
    Amthauer, H.
    Tacke, F.
    Roderburg, C.
    Hammerich, L.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 97 - 97
  • [9] Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study
    Hanae Ida
    Yoshitaka Honma
    Hidekazu Hirano
    Hirokazu Shoji
    Satoru Iwasa
    Natsuko Okita
    Atsuo Takashima
    Ken Kato
    Takahiro Fukuda
    Narikazu Boku
    Investigational New Drugs, 2019, 37 : 573 - 578
  • [10] Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study
    Ida, Hanae
    Honma, Yoshitaka
    Hirano, Hidekazu
    Shoji, Hirokazu
    Iwasa, Satoru
    Okita, Natsuko
    Takashima, Atsuo
    Kato, Ken
    Fukuda, Takahiro
    Boku, Narikazu
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (03) : 573 - 578
12345